OrganaBio

OrganaBio is a private, US-based biotech company founded in 2018 that operates as a Contract Technology Development and Manufacturing Organization (CTDMO) for the cell and gene therapy sector. It generates revenue by selling premium cellular starting materials and providing end-to-end development and manufacturing services, including clinical cell processing, cryopreservation, and custom cell isolation. The company's operational model is built on co-located donor collection and processing facilities, enabling rapid sample turnaround and high cell viability, which positions it as a strategic partner for pharmaceutical and biotech companies advancing allogeneic and autologous therapies. With a proven track record of processing thousands of clinical samples, OrganaBio supports innovators from early research through clinical trials.

Integrated CTDMO platform featuring an ethically sourced, recallable HLA-typed donor network; co-located rapid collection and processing facilities (under 30-minute turnaround); and a full suite of services from starting materials to clinical cell processing and cGMP manufacturing.

Competes with large, established CDMOs (e.g., Lonza, Catalent, Thermo Fisher) that offer cell therapy manufacturing and with specialized suppliers of human biological materials and primary cells. Differentiation is based on speed of processing, recallable donors, and an integrated service model tailored specifically for cell and gene therapy developers.